Height of children off therapy after acute lymphoblastic leukemia.
A total of 290 children off therapy after acute lymphoblastic leukemia, in continuous complete remission for at least 2 years, were evaluated for height at the onset of the disease and at the most recent clinical visit (median time after suspension of treatment 4 years 4 months, range 2 years-11 years 3 months). All patients had been treated with multidrug schedules; intrathecal drugs had been given to 84% of the patients for prevention of CNS involvement, associated with radiotherapy. The height percentiles at the most recent examination were shifted downward significantly compared with the expected pattern (p less than 0.001). The effect on stature was much more marked in girls, with a reduction of height percentiles at most recent examination from expected and from diagnosis; in males there was a reduction from diagnosis to latest follow-up, but the values were within the limits of normal. The short stature was mostly observed in pubertal girls and in patients who had undergone radiotherapy.
Zurlo
M G
MG
Department of Pediatrics, Ospedale S. Gerardo, Monza, Italy.
Senesi
E
E
Terracini
B
B
Balducci
D
D
Biddau
P
P
D'Angelo
P
P
Rosati
D
D
Gandus
S
S
Madon
E
E
Mancini
A
A
D000970:Antineoplastic Agents / Q000009:adverse effects; D001827:Body Height / Q000187:drug effects / Q000502:physiology*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology* / Q000628:therapy; D012074:Remission Induction / Q000379:methods; D012737:Sex Factors
D000970:Antineoplastic Agents